亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

作者
Songlin Mu,Zhijuan Liang,Yongmei Wang,Wendi Chu,Yi‐Li Chen,Qi Wang,Guifeng Wang,Chunhe Wang
出处
期刊:Clinical and translational medicine [Springer Science+Business Media]
卷期号:12 (5): e754-e754 被引量:22
标识
DOI:10.1002/ctm2.754
摘要

Although PD-1 and PD-L1 (programmed cell death-1/ligand 1) antibody therapies have provided persistent benefits in various cancers, their clinical applications have been limited by relatively low response rates and the occurrence of drug resistance.1 Thus, they have been extensively investigated in combination with a variety of antitumor therapies, such as inhibitors to other immune checkpoints in combinational or bispecific antibody (BsAb) therapeutical strategies, to improve the response rates or efficacies in the clinic.2 TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains) is an inhibitory T-cell immunoreceptor discovered in 2009,3 which is expressed mainly on regulatory T cells (Tregs), memory T-cells, and NK cells. Combination therapies that block both PD-L1 and TIGIT pathways have superior clinical benefits to PD-L1 monotherapy.4 BsAbs simultaneously targeting both pathways are also entering clinical trials (NCT05102214), but whether BsAbs are superior to combinational approaches has not been elucidated yet. We reported here a novel bispecific anti-PD-L1/TIGIT antibody with potent effects in enhancing human IL-2 production by primary human T cells in vitro and in increasing the overall survival in a transgenic mouse model in vivo. More importantly, we compared the tetravalent bispecific anti-PD-L1/TIGIT antibody to mAb and combination therapies head-to-head systematically, and our data supported the the advantage of taking bispecific approach over mAb and combination therapies experimentally. First, hybridomas were established5 and humanization was carried out through "framework shuffling6, 7 on both anti-PD-L1 and anti-TIGIT antibodies. Both chimeric (anti-PD-L1-8A1 and anti-TIGIT-31C3) and humanized (anti-PD-L1-#77, anti-TIGIT-T26 and T87) antibodies showed binding and blocking capabilities comparable to corresponding positive controls (Figure 1A–D), i.e., atezolizumab (Tencentriq) for anti-PD-L1 and tiragolumab for anti-TIGIT. Affinities were determined by biolayer interferometry (BLI) on OCTET and similar KD values were obtained (Figure S1). For further preclinical safety evaluation and in vivo efficacy studies, cross-reactive binding assays were evaluated, with high binding abilities to cynomolgus monkey antigen around 0.07 nM (anti-PD-L1) and 0.25–2.0 nM (anti-TIGIT), and no cross-reactivity to mouse antigen (Figure S2). The biological functions of mAbs were then examined. They all effectively boosted the cytokine release by activated human PBMC evaluated in SEB or anti-CD3/anti-CD28 stimulation assay in vitro (Figure 1E,F). Then the antitumor efficacy was investigated in a transgenic mouse model (C57BL/6-HU-PD-L1 or C57BL/6-HU-TIGIT), which expressed human PD-L1 or TIGIT as substitutes for mouse orthologs. Anti-PD-L1 antibody potently inhibited the tumour growth of MC38-hPD-L1 (Figure 1G; Figure S3) and anti-TIGIT inhibited MC38 cells (Figure 1H). Anti-PD-L1 antibodies also showed potent tumour suppression efficacy in C57BL/6 wild-type mice (Figure S4). To obtain a well-behaved anti-PD-L1/TIGIT molecule, eight BsAb antibodies (Bs#1–Bs#8) containing anti-TIGIT-huT26 or huT87 in IgG4, and anti-PD-L1-hu#77 in scFv were generated (Figure S5A). Additionally, the sequences of VH and VL in the scFv segment (VH-linker-VL and VL-linker-VH) with and without an additional disulphide bond mutation were taken into consideration.8 We measured the binding kinetics of eight BsAbs by BLI technology on Octet9 to both human PD-L1-his and human TIGIT-his, which indicated that the affinities to human PD-L1-his (6-9 nM) (Table 1) slightly decreased compared to humanized mAb (2.66 nM), but affinities to TIGIT were not affected (Figure S1). The binding and neutralization assays of eight BsAbs were analyzed by ELISA (Figure 2A–D) and Fluorescence Activated Cell Sorting (FACS) (Figure 2E–H). They all exhibited comparable binding and blocking capacities (Tables S1 and S2). However, Bs#5 to Bs#8 with the extra disulphide bond mutation had higher binding abilities on FACS. Bs#5 had the highest binding activities, with EC50 values of 0.85 nM for HEK293-hPD-L1 and 0.55 nM for HEK293-hTIGIT. Next, the purity and thermostability of BsAbs were evaluated through the HPLC-SEC method with native (non-treated) and heat-treated (60°C in a water bath for 1 h) BsAbs. The monomer ratios in native state and the decrease between the non-treated and heat-treated BsAbs revealed that BsAbs with a disulphide bond mutation in scFv (Bs#5 to Bs#8) had better purity (Table 1; Figure S5B). The disulphide bond mutation favoured the VH-linker-VL orientation in our BsAbs by comparing Bs#5 (2.5% decrease) to Bs#1 (11.7%), and Bs#6 (10.0% decrease) to Bs#2 (3.8%). Among them, Bs#5 with additional disulphide bond and in VH-linker-VL sequence showed better behaviour in purity and thermostability than other BsAbs. Based on our results, Bs#5 was selected as the BsAb candidate for further evaluation. The affinities and dual binding activity of Bs#5-hIgG1 (Bs#5.1) were detected by BLI (Figure 3A–D), which exhibited high affinities to both targets and outstanding dual-binding ability regardless of loading sequences of two antigens. Then, the biological functions of Bs#5.1 were explored in the SEB-activated PBMC experiment in vitro and double-gene humanized mouse model (C57BL/6-HU-PD-L1/TIGIT) in vivo. In the PBMC activation assay, Bs#5.1 increased the human IL-2 secretion sitmualted by SEB to the highest level (Figure 3E–H). In the animal study, Bs#5.1 treatment extended the survival time to the greatest extent and was the only group that showed a significant difference in overall survival compared to the isotype group (Figure 3I,J). However, the BsAb treatment failed to achieve a significant difference in tumour volume due to the great variability within the group. The tumour growth curves were displayed in Figure S6. The variability might arise from the relatively low dose regimen and the heterogenicity of hPD-L1 expression on MC38-hPD-L1 cells (Figure S3). Finally, pharmacokinetics (PK) analysis10 of Bs#5.1 was conducted in four female transgenic mice following a single dose injection of 10 mg/kg i.v., which showed similar PK curves by two ELISA methods, indicating that Bs#5.1 was intact and stable in mouse serum and capable of binding both targets (Figure S7). Currently, several bispecific antibodies targeting PD-L1/TIGIT (such as HLX301 from Henlius, Inc. and PM1022 from Biotheus Inc.) or PD-1/TIGIT (IBI321, jointly developed by Eli Lilly and Innovent Biologics, Inc.) have been advanced to Phase I clinical trials with no clinical antitumor efficacies reported yet. The combination therapy with PD-L1 and TIGIT inhibitors has demonstrated clinical benefits (CITYSCAPE study from Roche) in Phase II clinical trials. However,whether bispecific antibodies targeting PD-1 (or PD-L1) and TIGIT have advantage over mAb and combination therapies has not been demonstrated. Herein, we constructed a BsAb targeting both PD-L1 and TIGIT in the format of IgG-scFv and systematically characterized its functions in vitro and in vivo. BsAb induced the highest level of IL-2 production in primary human T cells when compared to the mAbs and combination. In the transgenic animal model, BsAb increased the overall survival to the greatest extent. Taken together, our data favour the BsAb approach over mAb and combination therapies. This work was supported by the China National Major Scientific and Technological Special Project (2019ZX09732002-006), the National Natural Science Foundation of China (81872785 and 81673347), Shanghai Municipal Commission of Science and Technology of China (17431904400, 19YF1457400 and 21S11904500), Institutes for Drug Discovery and Development, Chinese Academy of Sciences (CASIMM0120202007 and CASIMM0120202008), and Major Scientific and Technological Special Project of Zhongshan City (191022172638719 and 210205143867019). Yi-Li Chen is an employee of Shanghai Mabstone Biotechnologies, Ltd and Chunhe Wang is employed by both Shanghai Institute of Materia Medica and Dartsbio Pharmaceuticals, Ltd. The remaining authors declare no competing financial interests. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
超级的迎梅完成签到,获得积分10
1秒前
机智的白卉的应助被u680513采纳,获得10
3秒前
科研通AI6.3的应助被u680513采纳,获得10
7秒前
小蘑菇的应助被吴彦祖采纳,获得10
11秒前
15秒前
科研通AI6.4的应助被u855744采纳,获得10
21秒前
科研通AI6.3的应助被u855744采纳,获得10
23秒前
科研通AI6.3的应助被u264877采纳,获得10
23秒前
科研通AI6.2的应助被u855744采纳,获得10
25秒前
科研通AI6.3的应助被u855744采纳,获得10
25秒前
科研通AI6.2的应助被u264877采纳,获得10
28秒前
科研通AI6.3的应助被u264877采纳,获得10
29秒前
风吹麦浪的应助被u583484采纳,获得10
29秒前
科研通AI6.3的应助被u264877采纳,获得10
33秒前
漂亮的新梅完成签到,获得积分10
43秒前
七七完成签到 ,获得积分10
50秒前
忧郁的数据线关注了科研通微信公众号
56秒前
1分钟前
syvshc的应助被u721406采纳,获得10
1分钟前
u588294驳回了852的应助
1分钟前
1分钟前
1分钟前
遇上就这样吧给u266829的求助进行了留言
1分钟前
顺利手链完成签到,获得积分10
1分钟前
生动的昊焱完成签到,获得积分10
1分钟前
阿切尔代的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
吴彦祖发布了新的文献求助10
1分钟前
大胆醉卉完成签到,获得积分10
1分钟前
吴彦祖完成签到,获得积分10
1分钟前
识时务这也完成签到,获得积分10
1分钟前
烂漫琳完成签到,获得积分10
1分钟前
张哩哩完成签到,获得积分10
2分钟前
2分钟前
Jason完成签到,获得积分10
2分钟前
2分钟前
Jason发布了新的文献求助10
2分钟前
今后的应助被生锈的铁片采纳,获得10
2分钟前
务实寒烟完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206